Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Table 1 General presentation of the 10 patients with 'limited skin lupus' or toxiderma in a context of autoimmunity

Patient	Before anti-TNF alpha treatment				During onset of symptoms
	Disease	Autoantibody	Clinical signs of lupus	Treatment	Duration of treatment (months)	Clinical signs of lupus	Biological signs of lupus
1	RA, erosive	RF+	None	ETA	36	Skin	ANA+, dsDNA+
2	RA, erosive	RF+	None	INF	6	Skin	ANA+, dsDNA+
3	RA, erosive	RF+, ANA+ 1:160°	None	INF	18	Skin	ANA+, dsDNA+
4	RA, erosive	RF-	None	ETA	5	Skin	ANA+, dsDNA+
5	RA, erosive	RF+	None	INF	7	Skin	ANA+, dsDNA+
6	RA erosive	RF+	None	ETA	5	Skin	ANA+, dsDNA+
7	RA, erosive	RF+	None	INF	11	Skin	ANA+, dsDNA+
8	RA, erosive	RF+	None	INF	3	Skin	ANA+, dsDNA+
9	RA, erosive	RF+	None	ETA	12	Skin	ANA+, dsDNA+
10	RA, erosive	RF+	None	INF	13	Skin	ANA+, dsDNA+

ANA, antinuclear antibodies; dsDNA, double-strand DNA; ETA, etanercept; INF, infliximab; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor; +, positive; -, negative.

ISSN: 1478-6362